CellXperience Weekly https://cellxperience.com/newsletter/ Curated CellXperience briefing posts on stem cell, cell therapy, regenerative medicine, and evidence boundaries. en CellXperience Weekly - May 25, 2026 https://cellxperience.com/newsletter/cellxperience-weekly-2026-05-25/ https://cellxperience.com/newsletter/cellxperience-weekly-2026-05-25/ A seven-item issue covering CNS cell therapy, MSC/exosome trials, iPSC models, and product-quality guardrails. Mon, 25 May 2026 12:00:00 GMT A Five-Year Safety Read on Neural Stem Cells in Cervical Spinal Cord Injury https://cellxperience.com/newsletter/nsi566-cervical-sci-five-year-safety/ https://cellxperience.com/newsletter/nsi566-cervical-sci-five-year-safety/ A three-patient, five-year safety follow-up for direct NSI-566 neural stem cell implantation in chronic cervical spinal cord injury. Useful, but not an efficacy claim. Mon, 25 May 2026 12:00:00 GMT Reading the CB-Exo-A600 Alzheimer's Exosome Trial Before Results Exist https://cellxperience.com/newsletter/cb-exoa600-alzheimers-exosome-trial-design/ https://cellxperience.com/newsletter/cb-exoa600-alzheimers-exosome-trial-design/ A recruiting Phase 1/2 registry record for intranasal umbilical-cord MSC-derived exosomes in mild-to-moderate Alzheimer’s disease, read before efficacy claims arrive. Mon, 25 May 2026 12:00:00 GMT Japan's iPSC Parkinson's Approval Is Real Progress. The Boundary Is Still Hard. https://cellxperience.com/newsletter/japan-ipsc-parkinsons-amchepry-approval-evidence-boundary/ https://cellxperience.com/newsletter/japan-ipsc-parkinsons-amchepry-approval-evidence-boundary/ Japan’s conditional approval and reimbursement path for Amchepry/raguneprocel is real progress for iPSC-derived neural cell therapy, but the evidence remains early. Sat, 23 May 2026 12:00:00 GMT The Strange Part of This Parkinson's Organoid Paper Is Outside the Neuron https://cellxperience.com/newsletter/snca-triplication-organoid-extracellular-architecture-boundary/ https://cellxperience.com/newsletter/snca-triplication-organoid-extracellular-architecture-boundary/ A 2026 SNCA triplication midbrain organoid paper points to extracellular matrix remodeling before overt degeneration in the model, with a strict model-system boundary. Sat, 23 May 2026 12:00:00 GMT Reading NouvNeu001's Phase IIa and RMAT Signals Clearly https://cellxperience.com/newsletter/nouvneu001-phase-iia-rmat-parkinsons-cell-therapy-evidence/ https://cellxperience.com/newsletter/nouvneu001-phase-iia-rmat-parkinsons-cell-therapy-evidence/ iRegene’s NouvNeu001 has a U.S. Phase 1/2 registry record, sponsor-announced RMAT, and first U.S. dosing language. The claim remains early and source-bound. Sun, 24 May 2026 12:00:00 GMT Rezanecel Is Moving Toward the Trial Epilepsy Cell Therapy Needs https://cellxperience.com/newsletter/rezanecel-phase3-epilepsy-cell-therapy-trial-threshold/ https://cellxperience.com/newsletter/rezanecel-phase3-epilepsy-cell-therapy-trial-threshold/ Neurona’s rezanecel/NRTX-1001 has sponsor-reported open-label seizure-reduction signals and a serious Phase 3 path. The controlled trial remains the threshold. Sun, 24 May 2026 12:00:00 GMT